Oxford Biomedica PLC

Director's Dealing • Aug 22, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6631O

Oxford Biomedica PLC

22 August 2017

Director Dealings / Market Share Sale and Purchase

Oxford, UK - 22 August 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 21 August 2017 Tim Watts, Chief Financial Officer, exercised options over 8,244,169 ordinary shares of 1p each ("Ordinary Shares") in the Company.  The options were exercisable at a cost of 1p per share and Mr Watts has sold 965,374 shares at 8.6p in order to fund the £82,442 cost of exercise. These options were granted in 2012, 2013 and 2014 under the Company's 2007 Long Term Incentive Plan. 

Following the exercise Mr Watts holds 15,998,954 ordinary shares of 1p each ("Ordinary Shares") in the Company, 0.52% of the Company's issued share capital.

The issued share capital of the Company is 3,103,516,399 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton	Tel: +44 (0)20 3709 5700

Notes for editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPTMLTMBJTMJR